Phaseline

Companies › VitsGen Therapeutics

VitsGen Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
177Lu-PSMA-VG01
PSMA-targeting radioligand (lutetium-177 labeled)
FOLH1Phase 1PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07660211177Lu-PSMA-VG01Phase 1PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)OncologyMay 2027

Targets

FOLH1 (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Clarity Pharmaceuticals Convergent Therapeutics Fusion Pharmaceuticals Five Eleven Pharma T.O.A.D. Oncology Endocyte AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.